Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Mar 14, 2019 8:51am
202 Views
Post# 29484005

Execution...

Execution...PressRelease April 3, 2018....Genenews said (QUOTE) After nearly two years of very careful (I like very careful) preparation, the pieces are in place, and it is now a matter of execution (END of QUOTE).

After that PressRelease, all of a sudden, things started to happen very fast, like never before in the history of Genenews.

-Genenews switched Billing Company...
-Genenews restarted its Billing Process...
-Genenews entered into a partnership with AIM Laboratories...
-Genenews named David Byram Chief Commercial Officer...
-Genenews formed a partnership with LifeX...
-Genenews expanded coverage by Health Insurance network...
-Genenews declared steady revenue increase 3 quarters in a row(small but nevertheless a big step forward)...

PressRelease Dec 28, 2018...genenews said (QUOTE) Genenews is preparing for a very active first quarter in 2019, with plans already in place for screening of high-risk employe groups, implementation of screening within large HealthCare, and collaborating with one or more large Physician Network. (END of QUOTE).

Already in place , I like that.


There seem to be a lots of similirarity between this PressRelease and the April 3, 2018 PressRelease (execution).

Will be very interesting to see execution in 2019.
Bullboard Posts